HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human
Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to
Rituximab as Monotherapy or in Combination With Chemotherapy